Related Articles
The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients
Direct regulation of LAMP1 by tumor-suppressive microRNA-320a in prostate cancer
HMGB1 promotes the development of castration‑resistant prostate cancer by regulating androgen receptor activation
Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway Corrigendum in /10.3892/or.2022.8426
HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro